BONESUPPORT has terminated its present exclusive U.S. distribution agreement with Zimmer Biomet and will create its own U.S. commercial organization to support current and future U.S. product launches. BONESUPPORT's original distribution agreement with Biomet was signed in 2012; terms were extended in 1Q17. Direct sales will commence in October 2018.
The present commercial organization will grow from 12 to 23 people. BONESUPPORT's bone void filler product will be joined by new CERAMENT formulations, as well as other bone graft substitutes. The company is pursuing a 2021 launch of CERAMENT-G antibiotic eluting product, and will also develop partnerships to help complete its suite of offerings. Update: The company has signed an agreement with Collagen Matrix.
The FORTIFY clinical trial, which commenced enrollment in mid-2017, is assessing CERAMENT-G's ability to improve on the standard-of-care management of patients with open fractures of the tibial diaphysis.
Additional information is available in the webcast available online.
Sources: BONESUPPORT HOLDING AB; ORTHOWORLD Inc.